

Special Issue

Antibiotic Treatment and Antibiotic Resistance of Enterococcus Infections, 2nd Edition

Message from the Guest Editors

The first volume of the Special Issue “Antibiotic Treatment and Antibiotic Resistance of Enterococcus Infections” was published in 2022. Following its success, we are pleased to announce the launch of a second volume, focusing on the same topic. As a continuation of the Special Issue published in 2022, this second volume will also deliver an invaluable compendium of the latest treatments for Enterococcus infections and the latest research on antibiotic resistance in Enterococcus. Topics of interest may include, but are not limited to, the following:

- Epidemiological studies of enterococcal infection and trends in antibiotic resistance;
- Discoveries and genetic studies of new drug resistance genes in Enterococci;
- Surveillance of enterococcal resistance in healthcare settings;
- Antibiotic treatment of Enterococcus infections.

Guest Editors

Dr. Giovanni Boccia

Dr. Gianluigi Franci

Dr. Biagio Santella

Deadline for manuscript submissions

31 August 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/208479

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)